Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.

Espejo-Porras Francisco, et al.
Neuropharmacology, 2013

Abstract

The broad presence of CB1 receptors in the basal ganglia, mainly in GABA- or glutamate-containing neurons, as well as the presence of TRPV1 receptors in dopaminergic neurons and the identification of CB2 receptors in some neuronal subpopulations within the basal ganglia, explain the powerful motor effects exerted by those cannabinoids that can activate/block these receptors. By contrast, cannabidiol (CBD), a phytocannabinoid with a broad therapeutic profile, is generally presented as an example of a cannabinoid compound with no motor effects due to its poor affinity for the CB1 and the CB2 receptor, despite its activity at the TRPV1 receptor. However, recent evidence suggests that CBD may interact with the serotonin 5-HT1A receptor to produce some of its beneficial effects. This may enable CBD to directly influence motor activity through the well-demonstrated role of serotonergic transmission in the basal ganglia. We have investigated this issue in rats using three different pharmacological and neurochemical approaches. First, we compared the motor effects of various i.p. doses of CBD with the selective 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT; i.p.). Second, we investigated whether the motor effects of CBD are sensitive to 5-HT1A receptor blockade in comparison with CB1 receptor antagonism. Finally, we investigated whether CBD was able to potentiate the effect of a sub-effective dose of 8-OH-DPAT. Our results demonstrated that: (i) only high doses of CBD (>10 mg/kg) altered motor behavior measured in a computer-aided actimeter; (ii) these alterations were restricted to vertical activity (rearing) with only modest changes in other parameters; (iii) similar effects were produced by 8-OH-DPAT (1 mg/kg), although this agonist affected exclusively vertical activity, with no effects on other motor parameters, and it showed always more potency than CBD; (iv) the effects of 8-OH-DPAT (1 mg/kg) and CBD (20 mg/kg) on vertical activity were reversed by the 5-HT1A receptor antagonist WAY-100,635 (0.5 mg/kg; i.p.); (v) the effects of CBD (20 mg/kg) on vertical activity were not reversed by the CB1 receptor antagonist rimonabant (0.1 mg/kg; i.p.); (vi) the effect of 8-OH-DPAT on vertical activity was associated with an increase in serotonin content in the basal ganglia, a neurochemical change not produced by CBD (20 mg/kg); and (vii) CBD at a dose of 20 mg/kg was able to enhance motor effects of a sub-effective dose of 8-OH-DPAT (0.1 mg/kg), producing the expected changes in serotonergic transmission in the basal ganglia.

Conclusion

Collectively, these results suggest that CBD may influence motor activity, in particular vertical activity, and that this effect seems to be dependent on its ability to target the 5-HT1A receptor, a mechanism of action that has been proposed to account for its anti-emetic, anxiolytic and antidepressant effects.

Keywords

5-HIAA; 5-HT; 5-HT(1A) Receptors; 5-HT(1A) receptor; 5-hydroindolacetic acid; 8-OH-DPAT; 8-hydroxy-2-(di-n-propylamino) tetralin; CB(1) receptor; CB(2) receptor; CBD; CBDA; Cannabidiol; DOPAC; GABA; L-3,4-dihydroxyphenylacetic acid; Motor effects; PPAR; Serotonin; TRPV1; TRPV2; Transient receptor potential vanilloid type 1; Transient receptor potential vanilloid type 2; Vertical activity; cannabidiol; cannabidiolic acid; cannabinoid type 1 receptor; cannabinoid type 2 receptor; peroxisome-proliferating activator receptor; serotonin (5-hydroxytryptamine); serotonin type 1A receptor; Δ;(9)-THC; Δ;(9)-tetrahydrocannabinol; γ-aminobutiric acid.
>Copyright © 2013 Elsevier Ltd. All rights reserved.

PMID:23924692
DOI:10.1016/j.neuropharm.2013.07.024
Category:Brain / Mental Clarity

The best supplements with Cannabidiol or Cannabidiolic Acid in Brain / Mental Clarity category:

Articles similar to "Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors."

  • The significance of Cannabidiol for Brain / Mental Clarity: Antidepressant-like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa. (Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health...)
  • The role of Cannabidiol in Brain / Mental Clarity: A Systematic Review of the Effect of Cannabidiol on Cognitive Function: Relevance to Schizophrenia. (Background and objectives: Cognitive impairment is a core symptom domain of schizophrenia, neurological disorders and substance abuse... The efficacy of CBD to improve cognition in schizophrenia cannot be elucidated due to lack of clinical evidence; however, given the ability of CBD to restore cognition in multiple studies of impairment, further investigation into its efficacy in schizophrenia is warranted. Potential mechanisms underlying the efficacy of CBD to improve cognition are discussed. )
  • The impact of Cannabidiol on Brain / Mental Clarity: Evidences for the Anti-panic Actions of Cannabidiol. ( Panic disorder (PD) is a disabling psychiatry condition that affects approximately 5% of the worldwide population...)
  • The significance of Cannabidiol for Brain / Mental Clarity: Cannabidiol as a Potential Treatment for Anxiety Disorders. (Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders...)
  • The role of Cannabidiol in Brain / Mental Clarity: Cannabidiol, a Cannabis Sativa Constituent, as an Anxiolytic Drug. (Objectives: To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action... Future clinical trials involving patients with different anxiety disorders are warranted, especially of panic disorder, obsessive-compulsive disorder, social anxiety disorder, and post-traumatic stress disorders. The adequate therapeutic window of CBD and the precise mechanisms involved in its anxiolytic action remain to be determined.)
  • The impact of Cannabidiol on Brain / Mental Clarity: Cannabidiol, a Cannabis Sativa Constituent, as an Antipsychotic Drug. (A high dose of delta9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers... Future clinical trials involving patients with different anxiety disorders are warranted, especially of panic disorder, obsessive-compulsive disorder, social anxiety disorder, and post-traumatic stress disorders. The adequate therapeutic window of CBD and the precise mechanisms involved in its anxiolytic action remain to be determined.)
  • The role of Cannabidiol in Brain / Mental Clarity: Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. (Epilepsy is the most common neurological disorder, with over 50 million people worldwide affected... Future clinical trials involving patients with different anxiety disorders are warranted, especially of panic disorder, obsessive-compulsive disorder, social anxiety disorder, and post-traumatic stress disorders. The adequate therapeutic window of CBD and the precise mechanisms involved in its anxiolytic action remain to be determined.)
  • The impact of Cannabidiolic Acid on Brain / Mental Clarity: Acute oral cannabidiolic acid methyl ester reduces depression-like behavior in two genetic animal models of depression. (Background and purpose: Cannabidiolic acid methyl ester (HU-580) was recently shown to reduce stress-induced anxiety-like behavior in rats... Future clinical trials involving patients with different anxiety disorders are warranted, especially of panic disorder, obsessive-compulsive disorder, social anxiety disorder, and post-traumatic stress disorders. The adequate therapeutic window of CBD and the precise mechanisms involved in its anxiolytic action remain to be determined.)

Previous article

Cannabis Therapeutics and the Future of Neurology.

Next article

Acute oral cannabidiolic acid methyl ester reduces depression-like behavior in two genetic animal models of depression.